EH 6_2015

Weight-bearing3Dexams can get your patients back OnTrack. ©CarestreamHealth,Inc.,2015.CARESTREAMisatrademarkofCarestreamHealth. A world leader in diagnostic imaging is planning a revolution in Cone Beam CT. The CARESTREAM OnSight 3D Extremity System is being designed to be OnTarget with your needs – planned capabilities include weight-bearing extremity exams, easy patient access and superb 2D and 3D images. And, OnSight is projected to keep you OnBudget, with a price that’s truly affordable. So get ready – we’re designing OnSight to set a new pace for CBCT imaging. OnTrack. OnTarget. OnBudget. OnSight 3D Extremity System carestream.com INVESTIGATIONAL: NOT AVAILABLE FOR COMMERCIAL SALE This information for CBCT applies ONLY in the European Union. TRIM: 210mm X 297mm BLEED: + 5mm 220mm X 307mm www.healthcare-in-europe.com 3NEWS & MANAGEMENT notherapy brings ng successesdecade, have confirmed that seven to nine percent of all melanoma patients see a complete remission of their tumours. ‘Many more patients experience at least a lasting remis- sion,’ emphasises melanoma special- ist Professor Christoph Höller MD. ‘This is remarkable given the bad prognosis for this disease overall.’ Buoyed by the success achieved so far, the Viennese scientists are continuing to work on improve- ments of this treatment. Höller: ‘We are continuing to run studies on published in ‘Insights into Imaging’. This presents a knowledge base in multimodality imaging. In late 2014, a hybrid imaging training session was held at the Annual Leadership Meeting of the ESR’s European member societies, and the majority of attendees supported the establishment of a European society for hybrid imaging. An ESR survey showed that radiology residents also want to increase nuclear medicine training. The ESHI will be launched at the European Congress of Radiology next March. Membership will be open to radiologists and nuclear medicine physicians. immunotherapy. We’re research- ing the combination of the check- point inhibitors PD1 (Nivolumab) and CTLA4 (Ipilimumab). We are also starting a study where a PD-1 antibody will be combined with a genetically modified herpes virus.’ The virus will be injected into the metastases and results in the disin- tegration of the tumour cells. The fragments of the tumour cells then provoke a strong, local immune reaction, which is further increased by the administration of the anti- body. The basic principle of immu- notherapy is to activate the patient’s immune system and to direct it against the tumour cells. The so- called immune checkpoints play an important part here. These are receptor proteins found on the surface of T-cells (white blood cells boosting immune defence). When specific signal sub- stances (ligands) bind to the check- points the T-cells are slowed down. This mechanism serves the natural regulation of the immune system and prevents it from overshooting – as happens in the case of auto- immune diseases – and attacks the body’s own, healthy cells. However, tumour cells can also form ligands, which then inhibit the immune system via the checkpoints. Christoph Zielinski MD is head of the Oncology Department and is Chairman of the Board at the University Clinic for Internal Medicine I, Medical University of Vienna, where he also heads the Comprehensive Cancer Centre, as well as the Vienna General Hospital. A specialist in internal medicine and oncology, he spent three years at the Cancer Research Centre of Tufts University, Boston. Today his research lies on breast and lung cancer, the clinical development of drugs, transla- tional research, personalised medicine in oncology, and immunotherapy for cancer- ous diseases. With around 500 scientific publications to his name, and member- ships in international medical societies, he is also President of the Central European Cooperative Oncology Group (CECOG) and a member (2014-2015) of the Executive Committee of the European Society for Medical Oncology (ESMO). CCC/PhotographySabineGruber If the checkpoints of the T-cells can be blocked, thus preventing the ligands from binding to the receptors, this activates the T-cells and triggers an immune reaction and combat against the tumour. This blockade occurs via the much- quoted checkpoint inhibitors, i.e. humanised monoclonal antibodies administered via infusion. ‘For some types of advanced cancers treatment with checkpoint inhibitors can achieve a lasting response to treatment in around 20% of patients,’ Zielinski stress- es. New combination therapies are likely to significantly improve these results further still. cialty society: ng ©panthermedia.net/CathyYeulet

Pages Overview